Not Yet RecruitingNot Applicable

The Effect of Radiotherapy After Separation Surgery for Spinal Metastases

130 participantsStarted 2026-05-01

Plain-language summary

The aim of this clinical study is to explore the impact of whether radiotherapy is administered after spinal metastasis surgery on the prognosis and survival of patients, to describe the clinical outcomes, and to optimize future clinical decisions.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age over 18 years old, gender not limited;
✓. The patient has undergone separation surgery within 3 weeks;
✓. The pathological result of the separation surgery site of the patient indicates that the lesion is a metastatic tumor, and the primary lesion is located outside the spine;
✓. The expected survival period is ≥ 6 months;
✓. The patient has signed the informed consent form.

Exclusion criteria

✕. Patients with poor general condition and those who are intolerant to radiotherapy, chemotherapy, and targeted therapy;
✕. Patients whose treatment segments have not received any other surgical treatment or radiotherapy;
✕. Patients who participated in other clinical trials of drugs or medical devices within 3 months before enrollment;
✕. Other situations judged by the investigator as making the subject unsuitable for enrollment.

What they're measuring

Progression-Free Survival (PFS)

Timeframe: Baseline up to 24 months.

Trial details

NCT IDNCT07527884

SponsorShanghai Changzheng Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-05-01

Contact for this trial

Wei Xu

+8613761278657 xuwei_spine@163.com

View on ClinicalTrials.gov More Spinal Metastases trials